arrow
L

Laura Bucci

italian liver cancer association
H指数:35
被引数:6,083

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Letter: Improving the Interpretability and Portability of Tumour Burden Score–Based Prediction of Extrahepatic Progression After Transarterial Chemoembolisation (TACE)—Author's Reply

函件:改进基于肿瘤负荷评分的肝外进展预测(经动脉化疗栓塞术后)——作者回复

2026-03-090
OAAI
Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study

肿瘤负荷评分作为肝细胞癌经动脉化疗栓塞术后肝外进展的预测因子:一项多中心观察性研究

2026-01-140
PRE
Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study

肿瘤负荷评分作为肝细胞癌经动脉化疗栓塞术后肝外进展的预测指标:一项观察性多中心研究

2026-01-140
PRE
Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study

肿瘤负荷评分作为肝细胞癌经动脉化疗栓塞术后肝外进展的预测因子:一项多中心观察性研究

2026-01-140
PRE
Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study

肿瘤负荷评分作为肝细胞癌经动脉化疗栓塞术后肝外进展的预测指标:一项观察性多中心研究

2026-01-140
PRE
Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study

肿瘤负荷评分作为肝细胞癌经动脉化疗栓塞术后肝外进展的预测指标:一项观察性多中心研究

2026-01-140
PRE
Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study

肿瘤负荷评分作为肝细胞癌经动脉化疗栓塞术后肝外进展的预测指标:一项多中心观察性研究

2026-01-140
PRE
BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease

BCMA T细胞结合疗法在难治性自身免疫性疾病患者中的应用

2025-10-164
PRE
Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with refractory systemic lupus erythematosus – Authors' reply

局部免疫效应细胞相关毒性综合征在难治性系统性红斑狼疮CAR T细胞治疗患者中的应用——作者回复

2025-08-120
PRE
Outcome of hepatic resection for HCC in ideal and non-ideal candidates

理想和非理想候选者行肝切除治疗HCC的结局

2025-07-290
OA
Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world study

根据IMbrave050标准,肝细胞癌根治性切除或消融后的复发率、特征及结局:一项真实世界研究

2025-06-260
OA
Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study

自身免疫病患者CAR T细胞治疗相关的局部免疫效应细胞相关毒性综合征:一项观察性研究

2025-04-300
OAAI
BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells

BCMA CAR T细胞在一名接受初始及重复CD19 CAR T细胞疗法的复发性特发性炎性肌病患者中的表现

2025-04-171
OA
Absence of Viral Replication Is Associated With Improved Outcome in Anti-HCV-Positive Patients With Hepatocellular Carcinoma

丙型肝炎病毒复制缺失与抗HCV阳性肝细胞癌患者预后改善相关

2025-01-080
OAAI
Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care

索拉非尼和节律性卡培他滨在Child-Pugh B级晚期肝癌患者中的应用: 与最佳支持治疗的现实比较

2024-09-014
PRE
Bispecific T cell engager therapy for refractory rheumatoid arthritis
2024-04-2617
PRE
Characteristics and outcome of anti-hepatitis D virus positive patients with hepatocellular carcinoma
2024-03-012
OAAI
CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up

自身免疫性疾病的CD19 CAR T细胞治疗-病例系列随访

2024-02-22151
PRE